Our Story
About
Vision, team, and platform trajectory
Our Vision
From One Mutation to a Platform
Arcivus began with a single patient, a single mutation in the SGCE gene, and a question: could computational biology chart a path to precision gene therapy for a disease with no approved treatment?
That question became a platform. The architecture being built (patient-specific genetic characterization, mutation-informed strategy selection, AAV vector optimization, and translational development) is not specific to DYT-SGCE. It is a framework for rare neurological disease.
Rare diseases are not rare in aggregate. Over 7,000 known rare diseases affect 300 million people globally. Most share a common pattern: a single gene, a known mutation, and no approved therapy. Arcivus is building the infrastructure to change that, one disease at a time.
Our Team
Leadership
Co-Founder & Research Lead
Computational biology researcher focused on AAV gene therapy for rare neurological disorders. Published work on striatal D2 receptor upregulation in myoclonus-dystonia. Building Arcivus to bridge the gap between rare disease genetics and translational therapy development.
Roadmap
Platform Trajectory
n-of-1 Proof of Concept
Develop and validate AAV-SGCE gene replacement for a single patient. Build the computational and experimental pipeline.
SGCE Expansion
Generalize the pipeline to other DYT-SGCE patients with different mutation architectures. Vector optimization.
Monogenic Neuro Platform
Extend to other monogenic movement disorders and rare neurological diseases with analogous therapeutic logic.
AI-Driven Gene Therapy
Computational mutation analysis, automated construct design, patient-matched AAV delivery optimization.